The inhaled Rho kinase inhibitor Y-27632 protects against allergen-induced acute bronchoconstriction, airway hyperresponsiveness, and inflammation
Open Access
- 1 July 2008
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 295 (1), L214-L219
- https://doi.org/10.1152/ajplung.00498.2007
Abstract
Recently, we have shown that allergen-induced airway hyperresponsiveness (AHR) after the early (EAR) and late (LAR) asthmatic reaction in guinea pigs could be reversed acutely by inhalation of the Rho kinase inhibitor Y-27632. The present study addresses the effects of pretreatment with inhaled Y-27632 on the severity of the allergen-induced EAR and LAR, the development of AHR after these reactions, and airway inflammation. Using permanently instrumented and unrestrained ovalbumin (OA)-sensitized guinea pigs, single OA challenge-induced EAR and LAR, expressed as area under the lung function (pleural pressure, Ppl) time-response curve, were measured, and histamine PC100(provocation concentration causing a 100% increase of Ppl) values were assessed 24 h before, and at 6 and 24 h after, the OA challenge (after the EAR and LAR, respectively). Thirty minutes before and 8 h after OA challenge, saline or Y-27632 (5 mM) was nebulized. After the last PC100value, bronchoalveolar lavage (BAL) was performed, and the inflammatory cell profile was determined. It was demonstrated that inhalation of Y-27632 before allergen challenge markedly reduced the immediate allergen-induced peak rise in Ppl, without significantly reducing the overall EAR and LAR. Also, pretreatment with Y-27632 considerably protected against the development of AHR after the EAR and fully prevented AHR after the LAR. These effects could not be explained by a direct effect of Y-27632 on the histamine responsiveness, because of the short duration of the acute bronchoprotection of Y-27632 (<90 min). In addition, Y-27632 reduced the number of total inflammatory cells, eosinophils, macrophages, and neutrophils recovered from the BAL. Altogether, inhaled Y-27632 protects against acute allergen-induced bronchoconstriction, development of AHR after the EAR and LAR, and airway inflammation in an established guinea pig model of allergic asthma.Keywords
This publication has 46 references indexed in Scilit:
- Effects of Rho‐kinase inactivation on eosinophilia and hyper‐reactivity in murine airways by allergen challengesClinical and Experimental Allergy, 2007
- A guinea pig model of acute and chronic asthma using permanently instrumented and unrestrained animalsNature Protocols, 2006
- Differential Rho‐kinase dependency of full and partial muscarinic receptor agonists in airway smooth muscle contractionBritish Journal of Pharmacology, 2006
- Augmented acetylcholine‐induced, Rho‐mediated Ca2+ sensitization of bronchial smooth muscle contraction in antigen‐induced airway hyperresponsive ratsBritish Journal of Pharmacology, 1999
- Induction of hyperresponsiveness in human airway tiss by neutrophils — mechanism of actionClinical and Experimental Allergy, 1996
- The importance of eosinophil activation for the development of allergen‐induced bronchial hyperreactivity in conscious, unrestrained guinea‐pigsClinical and Experimental Allergy, 1994
- Inflammatory cells and eicosanoid mediators in subjects with late asthmatic responses and increases in airway responsivenessJournal of Allergy and Clinical Immunology, 1992
- Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsivenessJournal of Allergy and Clinical Immunology, 1991
- Anaphylaxis in guinea pigs induced by ovalbumin aerosol: In vivo and in vitro methodsJournal of Pharmacological Methods, 1987
- Mediators, airway responsiveness, and asthmaJournal of Allergy and Clinical Immunology, 1985